Breaking News

Ginkgo Bioworks Acquires Patch Biosciences

Strengthens its Gene Therapy Services, Cell Therapy Services, and RNA Therapeutics Services.

Author Image

By: Charlie Sternberg

Associate Editor

Ginkgo Bioworks has acquired Patch Biosciences, which has built an AI platform for sequence design that enables more effective, specific, and durable genetic medicines and was backed by Andreessen Horowitz (a16z) Bio + Health, Casdin Capital, and S32.   The acquisition is intended to strengthen Ginkgo’s Gene Therapy Services, Cell Therapy Services, and RNA Therapeutics Services.   The announcement follows the news that Ginkgo also recently acquired key assets of Reverie Labs and Proof ...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters